Kathryn has over 25 years experience in early and late drug development across multiple indications and platforms. She was partner at Takeda Ventures, Inc. and Head of Oncology Cell Therapy Development at Takeda Pharmaceuticals where she built capabilities and oversaw a cutting edge oncology cell therapy portfolio. Prior to that, she held several roles at Sanofi Genzyme and built a two decade career at Hoffman – La Roche, Roche Molecular Systems, Eli Lilly and Syndax, contributing to the approval of 6 new cancer therapies and expansion of multiple indications.

Dr. Bernhard Klemen spent more than 10 years at UBS, Morgan Stanley and J.P. Morgan in London and Frankfurt as well as Vienna, where he established the Austrian J.P. Morgan business. Since 2011 he has been a business angel and first investor as well as co-founder of more than 25 companies with scalable business models in tech and biotech. Between 2017-18 he became co-founder and raised, as international partner, the first international venture capital fund with a Pakistan focus - Sarmayacar. In 2018 he became an investor and board advisor supporting fundraising efforts for bit.bio before joining the company's executive team as CFO in 2021.

Dr Hermann Hauser is a serial entrepreneur and co-founder of Amadeus Capital Partners where he invested in CSR, Solexa, Icera, Xmos and Graphcore. Solexa created the dominant gene-sequencing technology now sold by Illumina. He has wide experience in developing and financing companies in the ICT and life science sector. He is a founder of Acorn Computers which created the ARM processor and helped spin it out with Apple into an independent company. He is vice-chair of the European Innovation Council, the €10bn deep tech fund of Horizon Europe.

Alan S. Roemer, MBA, MPH is an entrepreneurial life sciences executive and board member who has launched three multi-billion dollar biotechnology companies, raised over $1.75 billion in private and public capital, and consummated five IPOs. His senior leadership experience in development-stage biotechnology companies includes finance, accounting, business development, operations & administration, human resources, legal, information technology, facilities, corporate communications, and investor relations.

Roger is a pioneer and thought leader in the field of human stem cell biology. His lab was the first to isolate pluripotent epiblast stem cells from the epiblast layer of the developing mammalian embryo. In addition, he developed one of the first cellular reprogramming protocols. Roger was co-founder of the Cambridge Stem Cell Institute. His lab is currently focused on differentiation of pluripotent stem cells, with potential applications for drug discovery, toxicity testing and cell therapies.

After completing her medical studies in Rome and a post-doctoral fellowship focused on cellular immunology at the National Cancer Institute in Bethesda (USA), Dr Alteri spent 7 years in drug discovery and 5 years in clinical safety at Ciba-Geigy/Novartis in Basel. She was involved in major projects that yielded important drugs such as Gleevec for myeloid leukaemia, Coartem for malaria and Reyataz for HIV-AIDS. In 1998 she joined Serono in Geneva where she led the Pharmacovigilance and Risk Management team. At Serono, Dr Alteri was instrumental in establishing the company’s pharmacovigilance processes, as well as implementing the entire portfolio’s risk management strategy.
In 2012 she joined the European Medicines Agency, where she was Head of the Safety and Efficacy Sector for one year, being later promoted to Head of the Human Medicines Evaluation Division, and then to Head of the Human Medicines R&D Support Division.
She was member of the EMA Executive Board from 2013 until she retired in 2020.
In this roles, Dr Alteri was part of many high impact EMA’s initiatives, from the transparency of clinical trial data to the development of regulatory science strategy to 2025.
Dr Alteri has been consulting for the Swiss regulatory agency (Swissmedic), and is currently member of the Scientific Committee and faculty of the Master Course in Drug R&D of the University of Geneva. Dr Alteri regularly gives lectures on various aspects of R&D at the Universities of Rome, Cattolica and LUISS, and at the European Course in Pharmaceutical Medicine at the University of Basel. Moreover, she is member of the CIOMS Working Group XIII (Real World Data/Real World Evidence), and the CIOMS. Working Group Education. Most recently, she has been appointed as Core Member of the Proposal Review Committee of Unitaid for a 3-year period.

Marie-Claire is a pioneering international expert in sustainability, entrepreneurship, law and public policy. An award-winning expert jurist, executive and professor specialised in corporate social responsibility, climate law and governance, trade and investment, and research ethics, she also serves as Senior Director of the global Centre for International Sustainable Development Law (CISDL), advising the United Nations and key countries, and leading purpose-led companies on ethics and the UN Sustainable Development Goals